Suppr超能文献

用于口服给药的脂质纳米粒(固体脂质纳米粒和纳米结构脂质载体)的当前技术水平与新趋势

Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery.

作者信息

Severino Patrícia, Andreani Tatiana, Macedo Ana Sofia, Fangueiro Joana F, Santana Maria Helena A, Silva Amélia M, Souto Eliana B

机构信息

Department of Biotechnological Processes, School of Chemical Engineering, State University of Campinas (UNICAMP), 13083-970 Campinas, SP, Brazil.

出版信息

J Drug Deliv. 2012;2012:750891. doi: 10.1155/2012/750891. Epub 2011 Nov 24.

Abstract

Lipids and lipid nanoparticles are extensively employed as oral-delivery systems for drugs and other active ingredients. These have been exploited for many features in the field of pharmaceutical technology. Lipids usually enhance drug absorption in the gastrointestinal tract (GIT), and when formulated as nanoparticles, these molecules improve mucosal adhesion due to small particle size and increasing their GIT residence time. In addition, lipid nanoparticles may also protect the loaded drugs from chemical and enzymatic degradation and gradually release drug molecules from the lipid matrix into blood, resulting in improved therapeutic profiles compared to free drug. Therefore, due to their physiological and biodegradable properties, lipid molecules may decrease adverse side effects and chronic toxicity of the drug-delivery systems when compared to other of polymeric nature. This paper highlights the importance of lipid nanoparticles to modify the release profile and the pharmacokinetic parameters of drugs when administrated through oral route.

摘要

脂质和脂质纳米颗粒被广泛用作药物和其他活性成分的口服给药系统。它们在制药技术领域因许多特性而得到应用。脂质通常可增强药物在胃肠道(GIT)中的吸收,当制成纳米颗粒时,这些分子由于粒径小且能延长其在胃肠道的停留时间而改善黏膜黏附性。此外,脂质纳米颗粒还可保护所载药物免受化学和酶降解,并使药物分子从脂质基质中逐渐释放到血液中,与游离药物相比,从而改善治疗效果。因此,由于其生理和可生物降解特性,与其他聚合物性质的药物递送系统相比,脂质分子可能会降低药物递送系统的不良副作用和慢性毒性。本文强调了脂质纳米颗粒在通过口服途径给药时对改变药物释放曲线和药代动力学参数的重要性。

相似文献

1
Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery.
J Drug Deliv. 2012;2012:750891. doi: 10.1155/2012/750891. Epub 2011 Nov 24.
3
SLN and NLC for topical, dermal, and transdermal drug delivery.
Expert Opin Drug Deliv. 2020 Mar;17(3):357-377. doi: 10.1080/17425247.2020.1727883. Epub 2020 Feb 17.
4
Modification of oral absorption of oxyresveratrol using lipid based nanoparticles.
Colloids Surf B Biointerfaces. 2015 Jul 1;131:182-90. doi: 10.1016/j.colsurfb.2015.04.055. Epub 2015 May 4.
5
Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery.
AAPS PharmSciTech. 2011 Mar;12(1):62-76. doi: 10.1208/s12249-010-9563-0. Epub 2010 Dec 21.
6
8
Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs.
Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):499-515. doi: 10.1080/17425255.2019.1621289. Epub 2019 May 29.
10
Formulating SLN and NLC as Innovative Drug Delivery Systems for Non-Invasive Routes of Drug Administration.
Curr Med Chem. 2020;27(22):3623-3656. doi: 10.2174/0929867326666190624155938.

引用本文的文献

3
Design of lipid nanoparticle (LNP) containing genetic material CRISPR/Cas9 for familial hypercholesterolemia.
Narra J. 2025 Apr;5(1):e2217. doi: 10.52225/narra.v5i1.2217. Epub 2025 Apr 15.
4
Nanotherapy therapy for acute respiratory distress syndrome: a review.
Front Med (Lausanne). 2024 Dec 6;11:1492007. doi: 10.3389/fmed.2024.1492007. eCollection 2024.
5
Recent advances in essential oils and their nanoformulations for poultry feed.
J Anim Sci Biotechnol. 2024 Aug 10;15(1):110. doi: 10.1186/s40104-024-01067-8.
7
Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems.
Pharmaceutics. 2023 Sep 21;15(9):2363. doi: 10.3390/pharmaceutics15092363.
8
Current advances in nanodrug delivery systems for malaria prevention and treatment.
Discov Nano. 2023 Apr 20;18(1):66. doi: 10.1186/s11671-023-03849-x.

本文引用的文献

1
Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables.
Colloids Surf B Biointerfaces. 2011 Nov 1;88(1):483-9. doi: 10.1016/j.colsurfb.2011.07.036. Epub 2011 Jul 23.
2
A novel lipid nanocarrier for insulin delivery: production, characterization and toxicity testing.
Pharm Dev Technol. 2013 May-Jun;18(3):545-9. doi: 10.3109/10837450.2011.591804. Epub 2011 Jun 28.
3
Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel.
AAPS PharmSciTech. 2011 Jun;12(2):712-22. doi: 10.1208/s12249-011-9636-8. Epub 2011 Jun 3.
5
Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound.
Colloids Surf B Biointerfaces. 2011 Aug 1;86(1):158-65. doi: 10.1016/j.colsurfb.2011.03.035. Epub 2011 Apr 4.
7
Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation.
J Pharm Sci. 2011 Jun;100(6):2366-78. doi: 10.1002/jps.22435. Epub 2011 Jan 5.
9
Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles.
Int J Nanomedicine. 2011;6:547-55. doi: 10.2147/IJN.S17083. Epub 2011 Mar 15.
10
Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration.
Int J Pharm. 2011 May 30;410(1-2):138-44. doi: 10.1016/j.ijpharm.2011.02.064. Epub 2011 Mar 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验